Clarissa Uhlar

7.6k total citations · 2 hit papers
35 papers, 1.9k citations indexed

About

Clarissa Uhlar is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Clarissa Uhlar has authored 35 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 14 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Clarissa Uhlar's work include Multiple Myeloma Research and Treatments (21 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Clarissa Uhlar is often cited by papers focused on Multiple Myeloma Research and Treatments (21 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Clarissa Uhlar collaborates with scholars based in United States, Canada and Netherlands. Clarissa Uhlar's co-authors include Alexander S. Whitehead, Paul M. Sharp, Saad Z. Usmani, Huaibao Feng, Nizar J. Bahlis, Peter M. Voorhees, Liselotte E. Jensen, Sagar Lonial, Tahamtan Ahmadi and Brendan M. Weiss and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Clarissa Uhlar

33 papers receiving 1.9k citations

Hit Papers

Serum amyloid A, the major vertebrate acute‐phase reactant 1999 2026 2008 2017 1999 2016 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Serum amyloid A, the major vertebrate acute‐phase reactant
    1999 867 citations Clarissa Uhlar, Alexander S. Whitehead European Journal of Biochemistry profile →
  2. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
    2016 303 citations Saad Z. Usmani, Brendan M. Weiss et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Clarissa Uhlar United States 15 934 551 538 457 360 35 1.9k
Paul Coughlin Australia 21 965 1.0× 342 0.6× 726 1.3× 530 1.2× 106 0.3× 41 2.6k
Junichiro Fujimoto Japan 28 858 0.9× 397 0.7× 257 0.5× 720 1.6× 254 0.7× 124 2.6k
Marguerite S. Buzza United States 19 659 0.7× 206 0.4× 258 0.5× 475 1.0× 199 0.6× 29 1.7k
Marko Pesu Finland 26 822 0.9× 1.0k 1.9× 219 0.4× 1.3k 2.9× 236 0.7× 62 3.1k
Bruce D. Hultgren United States 18 836 0.9× 514 0.9× 982 1.8× 857 1.9× 596 1.7× 32 3.2k
Katherine A. Owen United States 17 670 0.7× 445 0.8× 229 0.4× 656 1.4× 109 0.3× 27 2.1k
Isao Hamaguchi Japan 23 1.9k 2.0× 488 0.9× 508 0.9× 873 1.9× 114 0.3× 122 3.2k
Thomas Hehlgans Germany 29 1.2k 1.2× 662 1.2× 238 0.4× 1.9k 4.2× 202 0.6× 71 3.4k
Steven D. Carson United States 30 965 1.0× 171 0.3× 819 1.5× 406 0.9× 431 1.2× 96 2.9k
Kazunori Imada Japan 29 639 0.7× 1.0k 1.8× 258 0.5× 1.9k 4.1× 165 0.5× 106 3.5k

Countries citing papers authored by Clarissa Uhlar

Since Specialization
Citations

This map shows the geographic impact of Clarissa Uhlar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clarissa Uhlar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clarissa Uhlar more than expected).

Fields of papers citing papers by Clarissa Uhlar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clarissa Uhlar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clarissa Uhlar. The network helps show where Clarissa Uhlar may publish in the future.

Co-authorship network of co-authors of Clarissa Uhlar

This figure shows the co-authorship network connecting the top 25 collaborators of Clarissa Uhlar. A scholar is included among the top collaborators of Clarissa Uhlar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clarissa Uhlar. Clarissa Uhlar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Costa, Luciano J., Nizar J. Bahlis, Saad Z. Usmani, et al.. (2024). Efficacy and Safety of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) With High-Risk (HR) Features: A Subgroup Analysis From the Phase 1/2 MajesTEC-1 Study. Clinical Lymphoma Myeloma & Leukemia. 24. S235–S235. 1 indexed citations
2.
Belch, Andrew, Torben Plesner, Paul G. Richardson, et al.. (2024). Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Carolina Digital Repository (University of North Carolina at Chapel Hill).
3.
Costa, Luciano J., Nizar J. Bahlis, Saad Z. Usmani, et al.. (2024). MM-328 Efficacy and Safety of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) With High-Risk (HR) Features: a Subgroup Analysis From the Phase 1/2 MajesTEC-1 Study. Clinical Lymphoma Myeloma & Leukemia. 24. S546–S547. 3 indexed citations
4.
Martin, Thomas G, María‐Victoria Mateos, Ajay K. Nooka, et al.. (2023). Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma. Cancer. 129(13). 2035–2046. 28 indexed citations
5.
Frerichs, Kristine A., Christie P.M. Verkleij, María‐Victoria Mateos, et al.. (2023). P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS. HemaSphere. 7(S3). e5193345–e5193345. 2 indexed citations
6.
Moreau, Philippe, Thierry Façon, Saad Z. Usmani, et al.. (2022). OAB-039: Treatment duration and long-term outcomes with daratumumab in transplant-ineligible newly diagnosed multiple myeloma from the phase 3 MAIA study. Clinical Lymphoma Myeloma & Leukemia. 22. S23–S24.
7.
Touzeau, Cyrille, Amrita Krishnan, Philippe Moreau, et al.. (2022). Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents.. Journal of Clinical Oncology. 40(16_suppl). 8013–8013. 26 indexed citations
8.
Usmani, Saad Z., Hareth Nahi, Torben Plesner, et al.. (2020). Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. The Lancet Haematology. 7(6). e447–e455. 74 indexed citations
9.
Usmani, Saad Z., Hareth Nahi, Brendan M. Weiss, et al.. (2017). Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and Sirius. Blood. 130. 3107–3107. 8 indexed citations
10.
Chari, Ajai, Suzanne Arinsburg, Sundar Jagannath, et al.. (2017). Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 18(1). 44–51. 26 indexed citations
11.
Usmani, Saad Z., Brendan M. Weiss, Torben Plesner, et al.. (2016). Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 128(1). 37–44. 303 indexed citations breakdown →
12.
Thomas, Sheeba K., А. Н. Суворов, Lucien Noens, et al.. (2013). Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma. Cancer Chemotherapy and Pharmacology. 73(1). 35–42. 11 indexed citations
13.
Robinson, Donald W., Janice N. Cormier, N. Zhao, et al.. (2011). Health-related quality of life among patients with metastatic melanoma. Melanoma Research. 22(1). 54–62. 14 indexed citations
14.
Uhlar, Clarissa & Alexander S. Whitehead. (1999). Serum amyloid A, the major vertebrate acute‐phase reactant. European Journal of Biochemistry. 265(2). 501–523. 867 indexed citations breakdown →
15.
Jensen, Liselotte E., Maura Hiney, Denis C. Shields, et al.. (1997). Acute phase proteins in salmonids: evolutionary analyses and acute phase response. The Journal of Immunology. 158(1). 384–392. 151 indexed citations
16.
Uhlar, Clarissa, et al.. (1996). Wallaby Serum Amyloid A Protein: cDNA Cloning, Sequence and Evolutionary Analysis. Scandinavian Journal of Immunology. 43(3). 271–276. 8 indexed citations
17.
Steel, Diana M., et al.. (1996). Expression and Regulation of Constitutive and Acute Phase Serum Amyloid A mRNAs in Hepatic and Non‐Hepatic Cell Lines. Scandinavian Journal of Immunology. 44(5). 493–500. 48 indexed citations
18.
Uhlar, Clarissa, et al.. (1994). Evolution of the Serum Amyloid A (SAA) Protein Superfamily. Genomics. 19(2). 228–235. 126 indexed citations
19.
Zahedi, Kamyar, Clarissa Uhlar, M Rits, Anne E. Prada, & Alexander S. Whitehead. (1994). The mouse interleukin 1 receptor antagonist protein: gene structure and regulation in vitro. Cytokine. 6(1). 1–9. 17 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul Coughlin Breakdown of academic impact, for papers by Junichiro Fujimoto Breakdown of academic impact, for papers by Marguerite S. Buzza Breakdown of academic impact, for papers by Marko Pesu Breakdown of academic impact, for papers by Bruce D. Hultgren Breakdown of academic impact, for papers by Katherine A. Owen Breakdown of academic impact, for papers by Isao Hamaguchi Breakdown of academic impact, for papers by Thomas Hehlgans Breakdown of academic impact, for papers by Steven D. Carson Breakdown of academic impact, for papers by Kazunori Imada
Rankless by CCL
2026